Related Experiment Video
Updated: Nov 23, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Targeted Therapies for Breast Cancer Brain Metastases
Ayse Ece Cali Daylan1, José Pablo Leone2
1Department of Medicine, St Elizabeth's Medical Center, Boston, MA; Department of Medicine, Tufts University School of Medicine, Boston, MA.
Abstract:
The management of breast cancer, the most common cancer in the female population, has changed dramatically over years with the introduction of newer therapies. An increased incidence of brain metastases in recent years has created a challenge for oncologists because this population continues to have a poorer prognosis compared to metastatic breast cancer without central nervous system involvement. Historically, the exclusion of breast cancer patients with brain metastases from clinical trials has made treatment options even more limited. Nonetheless, more recently, this unmet need has been recognized by basic and clinical researchers and has led to the development of targeted therapies with better blood-brain barrier penetration and intracranial efficacy. Here we review targeted therapies directed at human epidermal growth factor receptor type 2 (HER2), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), epidermal growth factor receptor (EGFR), cyclin-dependent kinase 4 and 6 (CDK4/6) and poly(ADP-ribose) polymerase (PARP) for breast cancer patients with brain metastases. These therapies aim to be more efficacious and less toxic to represent a paradigm shift in the management of breast cancer brain metastases.
Insights
New targeted therapies show promise for treating breast cancer brain metastases, offering improved efficacy and reduced toxicity. These advancements address a critical unmet need for patients with central nervous system involvement.
Area of Science:
- Oncology
- Translational Research
- Pharmacology
Background:
- Breast cancer is the most common cancer in women, with increasing incidence of brain metastases.
- Brain metastases in breast cancer patients are associated with a poorer prognosis and historically limited clinical trial participation.
- Limited treatment options for breast cancer with brain metastases represent a significant clinical challenge.
Purpose of the Study:
- To review recent advancements in targeted therapies for breast cancer brain metastases.
- To highlight therapies with improved blood-brain barrier penetration and intracranial efficacy.
- To discuss the potential paradigm shift in managing this complex patient population.
Main Methods:
- Review of targeted therapies including those targeting HER2, VEGF, mTOR, EGFR, CDK4/6, and PARP.
- Analysis of therapies developed to address the unmet need in breast cancer with central nervous system involvement.
- Focus on agents with demonstrated or potential intracranial efficacy.
Main Results:
- Development of targeted therapies with enhanced blood-brain barrier penetration.
- Emerging treatments show potential for improved efficacy in patients with brain metastases.
- Newer agents aim to be more efficacious and less toxic compared to historical treatments.
Conclusions:
- Targeted therapies represent a promising new direction for managing breast cancer brain metastases.
- These novel treatments offer hope for improved outcomes in patients with central nervous system involvement.
- Further research and clinical trials are crucial to fully realize the potential of these therapies.
